BACKGROUND & AIMS: Thiazolidinedione ligands for peroxisome proliferator-activated receptor gamma (PPARgamma), are used to treat diabetes. PPARgamma is highly expressed in the colon, and exposure to thiazolidinediones has been proposed to affect the risk for colorectal neoplasia. In vitro models suggest that thiazolidinediones have antineoplastic effects, whereas in vivo studies have produced mixed results: Some indicate an increased risk for intestinal tumors. This study examined the association between PPARgamma-targeted therapies and the risk of colonic neoplasia in patients with diabetes. METHODS: We conducted 3 retrospective case-control studies nested within the cohort of diabetic patients who were cared for within the Kaiser Permanente of Northern California system from 1994 to 2005. Case subjects were those with colonic neoplasia identified at the time of colonoscopy (study 1), sigmoidoscopy (study 2), or at follow-up lower endoscopy (study 3). Controls had no neoplasia identified at the endoscopic examination. A minimum of 1 year of therapy was used to define medication exposure. RESULTS: Fourteen thousand eighty-six patients were included. Among patients undergoing colonoscopy, there was an inverse association between thiazolidinedione exposure and prevalence of neoplasia (adjusted odd ratio [OR], 0.73; 95% confidence interval [CI], 0.57-0.92); however, this was not evident among patients without anemia (adjusted OR, 0.97; 95% CI, 0.64-1.49). Significant associations between any or long-term thiazolidinedione use and colonic neoplasia were not observed among patients undergoing sigmoidoscopy or serial lower endoscopies. CONCLUSIONS: These results indicate that thiazolidinedione therapy is not associated with an increased risk for colonic neoplasia.
BACKGROUND & AIMS:Thiazolidinedione ligands for peroxisome proliferator-activated receptor gamma (PPARgamma), are used to treat diabetes. PPARgamma is highly expressed in the colon, and exposure to thiazolidinediones has been proposed to affect the risk for colorectal neoplasia. In vitro models suggest that thiazolidinediones have antineoplastic effects, whereas in vivo studies have produced mixed results: Some indicate an increased risk for intestinal tumors. This study examined the association between PPARgamma-targeted therapies and the risk of colonic neoplasia in patients with diabetes. METHODS: We conducted 3 retrospective case-control studies nested within the cohort of diabeticpatients who were cared for within the Kaiser Permanente of Northern California system from 1994 to 2005. Case subjects were those with colonic neoplasia identified at the time of colonoscopy (study 1), sigmoidoscopy (study 2), or at follow-up lower endoscopy (study 3). Controls had no neoplasia identified at the endoscopic examination. A minimum of 1 year of therapy was used to define medication exposure. RESULTS: Fourteen thousand eighty-six patients were included. Among patients undergoing colonoscopy, there was an inverse association between thiazolidinedione exposure and prevalence of neoplasia (adjusted odd ratio [OR], 0.73; 95% confidence interval [CI], 0.57-0.92); however, this was not evident among patients without anemia (adjusted OR, 0.97; 95% CI, 0.64-1.49). Significant associations between any or long-term thiazolidinedione use and colonic neoplasia were not observed among patients undergoing sigmoidoscopy or serial lower endoscopies. CONCLUSIONS: These results indicate that thiazolidinedione therapy is not associated with an increased risk for colonic neoplasia.
Authors: G Steinbach; P M Lynch; R K Phillips; M H Wallace; E Hawk; G B Gordon; N Wakabayashi; B Saunders; Y Shen; T Fujimura; L K Su; B Levin; L Godio; S Patterson; M A Rodriguez-Bigas; S L Jester; K L King; M Schumacher; J Abbruzzese; R N DuBois; W N Hittelman; S Zimmerman; J W Sherman; G Kelloff Journal: N Engl J Med Date: 2000-06-29 Impact factor: 91.245
Authors: Robert S Sandler; Susan Halabi; John A Baron; Susan Budinger; Electra Paskett; Roger Keresztes; Nicholas Petrelli; J Marc Pipas; Daniel D Karp; Charles L Loprinzi; Gideon Steinbach; Richard Schilsky Journal: N Engl J Med Date: 2003-03-06 Impact factor: 91.245
Authors: Geoffrey D Girnun; Wendy M Smith; Stavit Drori; Pasha Sarraf; Elisabetta Mueller; Charis Eng; Prashant Nambiar; Daniel W Rosenberg; Roderick T Bronson; Winfried Edelmann; Raju Kucherlapati; Frank J Gonzalez; Bruce M Spiegelman Journal: Proc Natl Acad Sci U S A Date: 2002-10-07 Impact factor: 11.205
Authors: Andrew J Karter; Assiamira Ferrara; Jennifer Y Liu; Howard H Moffet; Lynn M Ackerson; Joe V Selby Journal: JAMA Date: 2002-05-15 Impact factor: 56.272
Authors: James D Lewis; Angela M Capra; Ninah S Achacoso; Assiamira Ferrara; Theodore R Levin; Charles P Quesenberry; Laurel A Habel Journal: Pharmacoepidemiol Drug Saf Date: 2007-11 Impact factor: 2.890
Authors: Yu-Xiao Yang; Laurel A Habel; Angela M Capra; Ninah S Achacoso; Charles P Quesenberry; Assiamira Ferrara; Theodore R Levin; James D Lewis Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-10-11 Impact factor: 4.254
Authors: Monica Franciosi; Giuseppe Lucisano; Emanuela Lapice; Giovanni F M Strippoli; Fabio Pellegrini; Antonio Nicolucci Journal: PLoS One Date: 2013-08-02 Impact factor: 3.240